In multiple myeloma and bladder cancer, KDM6A loss confers sensitivity to inhibitors of the EZH2 methyltransferase, while KDM6A loss in pancreatic cancers sensitizes to bromodomain and extra-terminal (BET) and histone deacetylase (HDAC) inhibitors (Table 2) (55, 58, 138–140). Here, KDM6A is linked to plasma cell myeloma.